Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX  
227.97
-0.64 (-0.28%)
4:02:56 PM EDT: $228.33 +0.36 (+0.16%)
Products, Earnings Announcements

Vertex Announces Results From Phase 2 Study Of Glomerulosclerosis Treatment

Published: 12/01/2021 12:42 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Announces Positive Results From Phase 2 Study of Vx-147 in Apol1-mediated Focal Segmental Glomerulosclerosis.
Vertex Pharmaceuticals Inc - Vertex to Advance Vx-147 Into Pivotal Development in Q1 2022.
Vertex Pharmaceuticals Inc - Vx-147 Was Well Tolerated.
Vertex - Vx-147 Treatment Led to Statistically Significant, Clinically Meaningful Mean Reduction in Proteinuria of 47.6% at 13 Weeks Versus Baselin.
Revenue is expected to be $2.01 Billion
Adjusted EPS is expected to be $3.29

Next Quarter Revenue Guidance is expected to be $2.03 Billion
Next Quarter EPS Guidance is expected to be $3.34

More details on our Analysts Page.